The FDA published a perspective on eliminating unnecessary animal studies, pushing developers toward more scientifically justified nonclinical packages and away from redundant preclinical work. While the document frames the goal as reducing avoidable animal testing, it also underscores how regulatory expectations may evolve around the use of non-animal methodologies.